WO1988009201A1 - Process and device for separating and cleaning molecules - Google Patents

Process and device for separating and cleaning molecules Download PDF

Info

Publication number
WO1988009201A1
WO1988009201A1 PCT/EP1988/000442 EP8800442W WO8809201A1 WO 1988009201 A1 WO1988009201 A1 WO 1988009201A1 EP 8800442 W EP8800442 W EP 8800442W WO 8809201 A1 WO8809201 A1 WO 8809201A1
Authority
WO
WIPO (PCT)
Prior art keywords
matrix
hollow body
molecules
solution
porous
Prior art date
Application number
PCT/EP1988/000442
Other languages
German (de)
French (fr)
Inventor
Metin Colpan
Ralf Piotrowiak
Original Assignee
Diagen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagen filed Critical Diagen
Publication of WO1988009201A1 publication Critical patent/WO1988009201A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/04Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
    • B01J20/048Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium containing phosphorus, e.g. phosphates, apatites, hydroxyapatites
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/06Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group B01J20/04
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28002Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
    • B01J20/28004Sorbent size or size distribution, e.g. particle size
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282Porous sorbents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282Porous sorbents
    • B01J20/283Porous sorbents based on silica
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282Porous sorbents
    • B01J20/284Porous sorbents based on alumina
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282Porous sorbents
    • B01J20/285Porous sorbents based on polymers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B01J20/287Non-polar phases; Reversed phases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/60Construction of the column
    • G01N30/6004Construction of the column end pieces
    • G01N30/603Construction of the column end pieces retaining the stationary phase, e.g. Frits
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/60Construction of the column
    • G01N30/6052Construction of the column body
    • G01N30/6065Construction of the column body with varying cross section
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/60Construction of the column
    • G01N30/6091Cartridges
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32Bonded phase chromatography
    • B01D15/325Reversed phase
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361Ion-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2220/00Aspects relating to sorbent materials
    • B01J2220/50Aspects relating to the use of sorbent or filter aid materials
    • B01J2220/64In a syringe, pipette, e.g. tip or in a tube, e.g. test-tube or u-shape tube
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/02Burettes; Pipettes
    • B01L3/0275Interchangeable or disposable dispensing tips
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8804Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 automated systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/10Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
    • G01N2035/1027General features of the devices
    • G01N2035/1048General features of the devices using the transfer device for another function
    • G01N2035/1055General features of the devices using the transfer device for another function for immobilising reagents, e.g. dried reagents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/26Conditioning of the fluid carrier; Flow patterns
    • G01N30/28Control of physical parameters of the fluid carrier
    • G01N30/34Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient

Definitions

  • the invention relates to a device and a method for separating and purifying molecules from a solution by adsorbing the molecules onto a matrix arranged in the device.
  • Chromatography materials of various types have long been used in a tried and tested way for sample preparation in chemically, biochemically and molecular biologically oriented laboratories. Frequently, the samples are obtained on a microscale, in particular in the bio-chemical and molecular biological, but also in the analytical-chemical laboratory.
  • the chromatographic materials are also used to extract certain components from the samples.
  • the procedure to be referred to as solid phase extraction can also be used to clean and separate substance mixtures in solution.
  • Removing and placing a storage container poses a risk of contamination for the employee, the environment and the sample itself.
  • the danger exists particularly in the medical-technical field, for example when working with infectious material, or also in biochemical-molecular biological Laboratories, especially when handling radioactive substances.
  • the object of the invention is therefore to provide a device which enables
  • the object is achieved according to the invention by a device which is characterized in that the Matrix 2 in a truncated cone-shaped hollow body 1 open at both ends 4a, 4b, to which a cylindrical hollow body adjoins optionally at the further opening 4a, permeable to the solution between two
  • Devices 3a, 3b is arranged, wherein the matrix 2 and the devices 3a, 3b together 5 to 50% of the
  • Fill the volume of the hollow body and the further opening 4a of the frustoconical hollow body 1 can be connected to a pipette.
  • Figures 1 and 2 show schematically the structure of a preferred embodiment of the device according to the invention.
  • the matrix 2 is delimited by two devices 3a, 3b which simultaneously ensure that the matrix 2 is fixed in the selected position.
  • the devices 3a, 3b are preferably clamped to the wall of the hollow body 1. However, in addition to fastening by tension, fastening by gluing the devices can also be achieved. Both methods lead to an adequate seal between the devices 3a, 3b and the wall of the hollow body 1.
  • the further opening 4a of the two openings 4a and 4b is designed such that they fit on a commercially available pipette.
  • a preferred embodiment of the device according to the invention consists in that the hollow body 1 is designed in the form of a pipette tip commercially available from specialist dealers (Brand, Gilson, Eppendorf).
  • the matrix 2 of the device according to the invention preferably consists of a porous chromatography material, in particular based on silica gel, aluminum oxide, titanium dioxide, hydroxylapatite, dextran, agarose, acrylamide, polystyrene, polyvinyl alcohol . or other organic polymers, derivatives or from copolymers of the abovementioned carrier materials.
  • the material forming the matrix 2 can also be a surface-modified, porous chromatography material based on silica gel, aluminum oxide, titanium dioxide,
  • Hydroxyapatite dextran, agarose, acrylic acid, polystyrene, polyvinyl alcohol or other organic polymers, derivatives or from copolymers of the abovementioned carrier materials.
  • ion exchange materials can be used as matrix 2 of the device according to the invention for the separation and purification of polar molecules.
  • Further preferred embodiments of the device according to the invention can contain a reversed-phase and / or an affinity chromatography material as matrix 2.
  • the pore size of the porous chromatography materials is preferably 20 to 1000 nm, and the grain size of the materials in particular 10 to 2000 ⁇ m, preferably 75 ⁇ m to 125 ⁇ m.
  • the devices 3a, 3b fixing the matrix 2 are preferably designed as porous frits with pore sizes of 10 ⁇ m to 1 mm, preferably 70 ⁇ m to 2000 ⁇ m.
  • the porous frits can consist of plastics, in particular Teflon (PTFE), polyethylene, polypropylene, polystyrene, polyurethane etc.
  • PTFE Teflon
  • inorganic materials such as glass and / or sintered metal are also suitable materials for the production of the porous frits.
  • FIGS. 3a and 3b show a further embodiment of the device according to the invention, the simple manufacture of which is particularly advantageous.
  • a removable cartridge 5 is inserted into the hollow body 1 and contains the matrix 2 between the devices 3a and 3b fixing the matrix.
  • the device 3b is arranged above a net-like carrier 6, which preferably consists of the same material as the removable cartridge 5.
  • the net-like carrier 6 and the cartridge 5 are produced in one operation, for example in the injection molding process, if cartridges are made of plastic, in particular polypropylene, the device 3a is arranged above the matrix 2 which in turn is arranged a porous, mesh-like cover 7.
  • FIG. 3b shows the overall arrangement, consisting of hollow body 1 and removable cartridge 5.
  • This overall arrangement, consisting of cartridge 5, devices 3a, b and cover 7 fixing the matrix 2 can be combined in a particularly advantageous manner with commercially available pipette tips become. In the simplest case, this is done by pushing the removable cartridge 5 into the corresponding hollow body 1, in particular a pipette tip.
  • the cartridge 5 is dimensioned so that it exerts a slight pressure on the inner walls of the pipette tip in order not to be pushed up when absorbing liquid or a sample or to provide the necessary seal to the inner wall of the hollow body 1, preferably a pipette tip, and the
  • the wall thickness of the removable cartridge 5 of the mesh-like carrier 6 and of the porous mesh-like cover 7 is matched to the pipette tip used.
  • the advantage of the device according to the invention lies in the practical handling and the type of packing of the matrix 2, which allows the solution containing the molecules to flow in the back and forth direction.
  • the frustoconical hollow body 1 is designed, for example, as a pipette tip, the pipette tip is immersed in the sample, the sample in the pipette tip is sucked up through the matrix 2 and then pressed out. This results in a higher efficiency of the adsorption, since the sample passes through the chromatographic material twice. Since it is possible to work with a closed system, contamination of the sample or danger to the environment is avoided.
  • the device according to the invention simplifies the overall method of operation which is to be used in the separation and purification of molecules.
  • biopolymers in particular nucleic acids and proteins, can also be fractionated quickly, easily and reliably.
  • the method according to the invention is carried out in a special embodiment with a hollow body 1 designed as a pipette tip.
  • the molecules containing, separating and cleaning the molecules can then be conveyed through the matrix 2 by means of a pipette. If the pipette tip is to be used as a column replacement in conventional processes, then - 1 -
  • the pipette tip can also be connected to a disposable syringe using a silicone tube.
  • the method according to the invention is suitable, in particular, for separating and purifying biopolymers such as nucleic acids and proteins by using ion exchange chromatography materials as proposed in German patent application P 36 39 949.3 as the matrix 2. It is silica gel-based chromatography material modified on the surface with anion exchange groups. If, for example, the matrix 2 is in a pipette tip, the nucleic acid is sucked through the matrix 2 with the pipette. The long-chain nucleic acids are adsorbed using buffers of low ionic strength. If you then want to utilize the short-chain nucleic acids, you push the solution back through the matrix 2 and catch it. Then further procedural steps can follow.
  • the long-chain nucleic acids can be eluted again by elution with buffers of high salt concentration (high ionic strength) and processed accordingly.
  • FIG. 4 shows an elution profile which can be obtained when anion exchange materials are used when using the device according to the invention. It has been shown that when using the material proposed for the separation of nucleic acids in German patent application P 36 39 949.3, an elution profile is obtained by means of which nucleic acids with increasing chain length can be eluted with increasing ionic strength. Thus, double-stranded DNA with base pairs> 500 is only obtained with an ionic strength of 1.3 M sodium chloride, while single-stranded DNA of the phage M 13 is eluted at 1.1 M sodium chloride. The elution peaks are so sharp that even "baseline" separations are possible. At an average ionic strength between 0.5 and 1 M sodium chloride, nucleic acids such as tRNA, 5 RNA and mRNA elute. At low ionic strengths of 0.1 to 0.5, polysaccharides,
  • Proteins such as BSA (bovine serum albumin) and smaller ones
  • a variant of the method consists in using an affinity adsorbent as matrix 2, as is proposed, for example, in German patent application P 36 27 063.
  • the procedure is carried out analogously to the procedure described above.
  • the method according to the invention ensures the following advantages, in particular in molecular biological operations:
  • the purity in routine preparations obtainable when using the device according to the invention is at least comparable to samples obtained by Caesiu chloride density gradient centrifugation.
  • the isolated nucleic acids are free of proteins, polysaccharides and other cell metabolites and show no inhibition of enzymes in enzymatic reactions.
  • the device according to the invention can be used for the isolation and purification of nucleic acids from oligonucleotides to plasmids, the time expenditure being restricted to fractions in comparison to other processes.
  • the device according to the invention is suitable for use in a separation and purification process for molecules, preferably biopolymers such as proteins and / or nucleic acids, in particular of other cell components.
  • the use of the device according to the invention in various processes is explained in more detail in the following examples.
  • the device according to the invention is used in a preferred embodiment, the pipette tip.
  • a 70 ⁇ polyethylene frit with a 4 mm diameter and a thickness of 1.6 mm is introduced into a 1 ml pipette tip, suitable for Gilson Pipetan, and clamped by pressing. Then about 70 mg of the chromatographic material, proposed in German patent application P 36 39 949, are filled in dry. The chromatographic material is closed with a 5.7 mm diameter frit as described above and the frit is fixed in place by pressing. The procedure is analogous for 200 ⁇ l pipette tips or 5000 ⁇ l pipette tips.
  • the pipette tip is equilibrated once with 100 ⁇ l of a suitable adsorption buffer. With a sample volume of 100 to 200 ⁇ l to be processed, it is sufficient to push the sample through the chromatography material about five times. However, if a larger amount of liquid is to be processed, such as is obtained after gel elution, the sample can be drawn through the matrix using a silicone tube that connects the pipette tip and a disposable syringe. It is then sufficient for the sample to pass the chromatography material only twice. The flow rate of the solution should not be higher than 1 ml per minute.
  • Buffer A can be used as equilibration and adsorption buffer. Buffer A:
  • buffers B, C and D are typically used as washing buffers.
  • Buffer B Buffer C:
  • An Eppendorf tube is filled with 1 ml of washing buffer and 150 ⁇ l are rinsed three times through the chromatography material in order to remove impurities. This step is repeated.
  • the adsorbed nucleic acids are eluted either with an Eppendorf or Gilson pipette or with a disposable syringe, care being taken that the pipette tip is connected to the disposable syringe by means of a silicone tube. It simply becomes the elution buffer E or F
  • Buffer E Buffer F:
  • a pipette tip, produced according to Example 1, is hydrated with 50 mM sodium phosphate buffer and equilibrated by passing 750 ⁇ l buffer several times through the
  • Pipette sucks.
  • a plasmid DNA sample is typically obtained in a so-called mini-preparation by the following steps:
  • the bacterial cells are incubated overnight and harvested the next day by centrifugation.
  • the pellet is disrupted in 85 ⁇ l of an ice-cold solution of 50 mM Tris-HCl, pH 7.4, with 2 mg / ml lysozyme (freshly prepared) and incubated on ice for 10 minutes.
  • 20 ⁇ l of a 0.5 M EDTA solution are added and incubated for a further 10 minutes.
  • After adding 4 ⁇ l of 2% Triton X '100 the mixture is incubated on ice for a further hour.
  • the sample is centrifuged in a laboratory centrifuge for 30 minutes at maximum speed, and 100 ⁇ l of the cell lysate freed from cell debris are transferred to another Eppendorf tube, after which 1 volume of 2 M sodium chloride, 100 mM MOPS, pH 7 and 5 ⁇ l Isoa yl alcohol can be added.
  • a pipette tip according to the invention from Gilson, Brand, Eppendorf, manufactured according to Example 1, is equilibrated with 100 ⁇ l buffer C. Then 100 ⁇ l of an E. coli plasmid DNA sample is adsorbed on the chromatography material by pipetting the sample up and down five times.
  • RNA extract is precipitated with ethanol and the pellet obtained is resuspended in TE buffer (10 mM Tris / 1 mM EDTA, pH 7.5).
  • TE buffer 10 mM Tris / 1 mM EDTA, pH 7.5.
  • the adsorption conditions are adjusted by adding 0.1 part by volume (based on the re-suspended solution) of 5 M sodium chloride and 0.2 part by volume of 250 mM MOPS, pH 7.0.
  • the pipette tip is equilibrated with 1 ⁇ l buffer A.
  • the sample is then adsorbed onto the chromatography material by pipetting up and down five times. One rinses with buffer A in order to eliminate impurities. Elution is carried out with 300 ⁇ l of buffer C.
  • the RNA is precipitated by adding 2.5 parts by volume of ethanol. After standing at -20 ° C. for 30 minutes, centrifugation in an Eppendorf centrifuge takes a total of 30 minutes at the highest speed. The pellet
  • the labeling reaction of the DNA is terminated by adding 2 ⁇ l 0.5 M EDTA per 20 ⁇ l sample volume, and the adsorption conditions are adjusted by adding 1 volume part of the buffer C.
  • the total final salt concentration should be approximately 500 mM.
  • the pipette tip according to the invention is equilibrated with 100 ⁇ l buffer B.
  • the sample is adsorbed onto the chromatography material by suction up five times and squeezed out and washed with a total of 10 ml of buffer B in order to separate the unreacted nucleotides.
  • the flow rate of the washing buffer should preferably be approximately 5 ml per minute.
  • the labeled DNA is then eluted with a total of 300 ⁇ l of the buffer F.
  • the sample can be used directly if it is diluted at least 1:20 with the buffer intended for hybridization. Otherwise the sample is precipitated and dissolved in TE buffer.
  • the removal of a DNA linker from a DNA with more than approx. 400 base pairs in a cloning experiment is carried out as follows:
  • the sample to be cleaned is diluted with 1 part by volume of the buffer C so that the final concentration of salt is approximately 500 mM.
  • the pipette tip according to the invention is equilibrated with 100 ⁇ l of buffer A.
  • the sample is adsorbed as in the previous examples.
  • the pipette tip according to the invention is rinsed with buffer B in order to remove the contaminants.
  • the DNA is desorbed and eluted with a total of 300 ⁇ l of buffer F.
  • DNA is isolated by isopropanol precipitation (addition of 1 part by volume) and left on ice for 15 minutes, after which the sample is centrifuged in an Eppendorf centrifuge for the Duration of 30 minutes. Then wash carefully with 70% ethanol.
  • the underlying reaction volume is 50 ⁇ l and contains no more than 100 mM sodium chloride. 5 ⁇ l of 0.5 M EDTA, pH 8.0, are added to the reaction volume in order to terminate the modification reaction. A volume part of the buffer C is added in order to set the adsorption conditions with a salt concentration of about 500 mM.
  • the pipette tip according to the invention is equilibrated, the sample is adsorbed and then eluted as described in Example 8. The further treatment of the sample is also carried out as described in Example 8.
  • the device according to the invention can also be used to efficiently separate agarose and acrylamide impurities. This is particularly necessary when gel elution of the sample has taken place.
  • the DNA is concentrated at the same time, even if the starting volume is a few ml.
  • the DNA has a size of> 400 base pairs and can be present in an amount from 5 ng to 15 ⁇ g.
  • the sample preparation and the equilibration of the pipette tip according to the invention is carried out as described in Example 8.
  • the sample is then transferred to a disposable syringe and pressed twice through the pipette tip according to the invention.
  • the flow rate should be around 250 ⁇ l / in.
  • the pipette tip according to the invention is then washed with 5 ml of buffer B at a flow rate of 5 ml / min.
  • the further treatment of the DNA sample is carried out as described in Example 8.

Abstract

In a device for separating and cleaning molecules by adsorption of the molecules on a matrix (2), the solution is forced through the device. The matrix (2) is arranged, between two devices (3a, 3b) permeable to the solution, in a hollow frustum-shaped body (1) open at both ends (4a, 4b), the wider opening (4a) being connected, if necessary, to a cylindrical hollow body. The matrix (2) and the devices (3a, 3b) together occupy 5 to 50% of the volume of the hollow body and the wider opening (4a) of the hollow frustum-shaped body (1) can be connected to a pipette. The use of the device in a process for separating and cleaning molecules on a matrix is also described.

Description

Vorrichtuncf und Verfahren zur Trennung- und Reinigung vonDevice and method for separating and cleaning
MolekülenMolecules
Die Erfindung betrifft eine Vorrichtung und ein Verfah¬ ren zur Trennung und Reinigung von Molekülen aus einer Lösung durch Adsorption der Moleküle an eine in der Vorrichtung angeordneten Matrix.The invention relates to a device and a method for separating and purifying molecules from a solution by adsorbing the molecules onto a matrix arranged in the device.
Zur Probenaufbereitung in chemisch, biochemisch und molekularbiologisch orientierten Laboratorien werden Chromatographiematerialen unterschiedlichster Art seit langem in bewährter Weise verwendet. Häufig fallen da¬ bei die Proben in Mikromaßstab an, insbesondere im bio¬ chemischen und molekularbiologischen, aber auch im ana¬ lytisch-chemischen Laboratorium. Die chromatographi¬ schen Materialien werden auch zur Extraktion von be¬ stimmten Bestandteilen aus den Proben eingesetzt. Die als Festphasenextraktion zu bezeichnende Verfahrenswei¬ se kann man sich auch zur Reinigung und Trennung von Substanzgemischen in Lösung zunutze machen. Bislang wurden neben den Chromatographiesäulen, insbesondere in der Hochdruckflüssigkeitschro atographie, auch Kartu¬ schen, Einwegspritzen oder kleine Plastikchro atogra- phiesäulen, die jeweils mit dem gewünschten Chromato¬ graphiematerial gefüllt sind, verwendet.Chromatography materials of various types have long been used in a tried and tested way for sample preparation in chemically, biochemically and molecular biologically oriented laboratories. Frequently, the samples are obtained on a microscale, in particular in the bio-chemical and molecular biological, but also in the analytical-chemical laboratory. The chromatographic materials are also used to extract certain components from the samples. The procedure to be referred to as solid phase extraction can also be used to clean and separate substance mixtures in solution. Up to now, in addition to the chromatography columns, in particular in high-pressure liquid chromatography, cartridges, disposable syringes or small plastic chromatography columns, each filled with the desired chromatography material, have been used.
Diese Hilfsmittel, die im Niederdruckbereich Verwendung finden, zeichnen sich unvorteilhaft dadurch aus, daß sie nicht mit etablierten Laboratoriumsgerätschaften kompatibel sind. Ein weiterer Nachteil dieser Hilfsmit¬ tel besteht darin, daß sie nur eine Flußrichtung der die zu trennenden und reinigenden Moleküle enthaltenden Lösung zulassen. Man muß also bei der Verfahrensweise gemäß dem Stand der Technik die Probe zunächst in ein Vorratsgefäß, beispielsweise eine Einwegspritze, brin¬ gen, um sie dann durch das Flußmittel, insbesondere Kartuschen oder Extraktionssäulen, zu drücken. Daher bedient man sich in der Praxis dieser Hilfsmittel überwiegend dann, wenn man die unerwünschten Produkte adsorbieren will. Ansonsten muß man das Vorratsgefäß, beispielsweise die Einwegspritze, entfernen, mit einem die adsorbierte Substanz eluierenden Lösung erneut be- schicken und anschließend durch das Hilfsmittel drucken, um die gewünschten Produkte zu erhalten. Durch das Ab¬ nehmen und Aufsetzen eines Vorratsgefäßes besteht je¬ doch eine Kontaminationsgefahr für den Mitarbeiter, die Umwelt und die Probe selbst. Die Gefahr besteht gerade im medizinisch-technischen Bereich, wenn beispielsweise mit infektiösem Material gearbeitet wird, oder auch in biochemisch-molekularbiologischen Laboratorien, wenn insbesondere mit radioaktiven Substanzen hantiert wird.These tools, which are used in the low pressure range, are disadvantageously characterized in that they are not compatible with established laboratory equipment. Another disadvantage of these auxiliaries is that they only allow one direction of flow of the solution containing the molecules to be separated and purified. In the procedure according to the prior art, the sample must first be placed in a storage vessel, for example a disposable syringe, in order to then push it through the flux, in particular cartridges or extraction columns. Therefore, in practice, these aids are mainly used when you want to adsorb the unwanted products. Otherwise, the storage vessel, for example the disposable syringe, has to be removed, re-loaded with a solution eluting the adsorbed substance and then printed through the auxiliary in order to obtain the desired products. Removing and placing a storage container poses a risk of contamination for the employee, the environment and the sample itself. The danger exists particularly in the medical-technical field, for example when working with infectious material, or also in biochemical-molecular biological Laboratories, especially when handling radioactive substances.
In der Praxis besteht ein erheblicher Bedarf an einer Vorrichtung, die es in einfacher Weise ermöglicht, ein Verfahren zur Reinigung und Trennung von Molekülen aus einer Lösung durchzuführen.In practice, there is a considerable need for a device which enables a method for purifying and separating molecules from a solution to be carried out in a simple manner.
Aufgabe der Erfindung ist es also, eine Vorrichtung bereitzustellen, die es ermöglicht,The object of the invention is therefore to provide a device which enables
- Moleküle aus einer Lösung zu extrahieren,- extract molecules from a solution,
- keine bevorzugte Extraktions- oder Elutionsrichtung zu verlangen, eine Abtrennung und Wiederhinzufügung eines Vorrats¬ gefäßes zu vermeiden,to request no preferred extraction or elution direction, to avoid a separation and re-addition of a storage vessel,
- die Trennungs- und Reinigungsoperationen in einem geschlossenen System durchzuführen, die Kontaminationsgefahr für Personal, Umwelt und Probe zu vermeiden, und gleichzeitig die Arbeitsweise insgesamt zu erleich¬ tern.- to carry out the separation and cleaning operations in a closed system, to avoid the risk of contamination for personnel, the environment and the sample, and at the same time to facilitate the overall working method.
Die Aufgabe wird erfindungsgemäß gelöst durch eine Vor¬ richtung, die dadurch gekennzeichnet ist, daß die Matrix 2 in einem an beiden Enden 4a, 4b offenen, ke¬ gelstumpfförmigen Hohlkörper 1, an den gegebenenfalls an der weiteren Öffnung 4a ein zylindrischer Hohlkörper anschließt, zwischen zwei für die Lösung durchlässigenThe object is achieved according to the invention by a device which is characterized in that the Matrix 2 in a truncated cone-shaped hollow body 1 open at both ends 4a, 4b, to which a cylindrical hollow body adjoins optionally at the further opening 4a, permeable to the solution between two
Einrichtungen 3a, 3b angeordnet ist, wobei die Matrix 2 und die Einrichtungen 3a, 3b zusammen 5 bis 50% desDevices 3a, 3b is arranged, wherein the matrix 2 and the devices 3a, 3b together 5 to 50% of the
Hohlkörpervolumens ausfüllen und die weitere Öffnung 4a des kegelstumpfförmigen Hohlkörpers 1 an eine Pipette anschließbar ist.Fill the volume of the hollow body and the further opening 4a of the frustoconical hollow body 1 can be connected to a pipette.
Die Figuren 1 und 2 zeigen schematisch den Aufbau einer bevorzugten Ausführungsform der erfindungsgemäßen Vor¬ richtung. Die Matrix 2 wird von zwei Einrichtungen 3a, 3b begrenzt, die gleichzeitig dafür sorgen, daß die Matrix 2 in der gewählten Position fixiert ist. Die Einrichtungen 3a, 3b werden vorzugsweise an der Wandung des Hohlkörpers 1 festgeklemmt. Es kann jedoch neben der Befestigung durch Spannung auch eine Befestigung durch Festkleben der Einrichtungen erreicht werden. Beide Methoden führen zu einer hinreichenden Abdichtung zwischen den Einrichtungen 3a, 3b und der Wand des Hohlkörpers l. Vorzugsweise findet sich zwischen der unteren Einrichtung 3b und der engeren Öffnung 4b ein freier Raum, wobei dieser freie Raum klein sein soll gegenüber dem Gesamtvolumen des Hohlkörpers. Die wei¬ tere Öffnung 4a der beiden Öffnungen 4a und 4b ist so ausgestaltet, daß sie auf eine handelsübliche Pipette passen. Eine bevorzugte Ausführungsform der erfindungs¬ gemäßen Vorrichtung besteht darin, daß der Hohlkörper 1 in Form einer kommerziell im Fachhandel erhältlichen Pipettenspitze (Firma Brand, Gilson, Eppendorf) ausge¬ staltet ist. Die Matrix 2 der erfindungsgemäßen Vor¬ richtung besteht vorzugsweise aus einem porösen Chroma¬ tographiematerial, insbesondere auf der Basis von Sili- cagel, Aluminiumoxid, Titandioxid, Hydroxylapatit, Dex- tran, Agarose, Acrylamid, Polystyrol, Polyvinylalkohol' oder anderen organischen Polymeren, Derivaten oder aus Copolymeren der oben genannten Trägermaterialien. Das die Matrix 2 bildende Material kann auch ein oberfläch¬ lich modifiziertes, poröses Chromatographiematerial auf der Basis von Silicagel, Aluminiumoxid, Titandioxid,Figures 1 and 2 show schematically the structure of a preferred embodiment of the device according to the invention. The matrix 2 is delimited by two devices 3a, 3b which simultaneously ensure that the matrix 2 is fixed in the selected position. The devices 3a, 3b are preferably clamped to the wall of the hollow body 1. However, in addition to fastening by tension, fastening by gluing the devices can also be achieved. Both methods lead to an adequate seal between the devices 3a, 3b and the wall of the hollow body 1. There is preferably a free space between the lower device 3b and the narrower opening 4b, this free space should be small compared to the total volume of the hollow body. The further opening 4a of the two openings 4a and 4b is designed such that they fit on a commercially available pipette. A preferred embodiment of the device according to the invention consists in that the hollow body 1 is designed in the form of a pipette tip commercially available from specialist dealers (Brand, Gilson, Eppendorf). The matrix 2 of the device according to the invention preferably consists of a porous chromatography material, in particular based on silica gel, aluminum oxide, titanium dioxide, hydroxylapatite, dextran, agarose, acrylamide, polystyrene, polyvinyl alcohol . or other organic polymers, derivatives or from copolymers of the abovementioned carrier materials. The material forming the matrix 2 can also be a surface-modified, porous chromatography material based on silica gel, aluminum oxide, titanium dioxide,
Hydroxylapatit, Dextran, Agarose, Aσryla id, Polysty¬ rol, Polyvinylalkohol oder anderen organischen Polyme¬ ren, Derivaten oder aus Copolymeren der oben genannten Trägermaterialien sein.Hydroxyapatite, dextran, agarose, acrylic acid, polystyrene, polyvinyl alcohol or other organic polymers, derivatives or from copolymers of the abovementioned carrier materials.
Die Wahl des entsprechenden Chromatographiematerials ist abhängig von den jeweiligen zu trennenden und rei¬ nigenden Molekülen und dem Fachmann aufgrund der Regeln der Chromatographie bekannt. So wird beispielsweise ein polares Molekül, wenn es an der Matrix 2 adsorbiert werden soll, nur dann an der Oberfläche der Matrix 2 adsorbiert, wenn entsprechende Wechselwirkungen vorlie¬ gen, die beispielsweise ebenfalls durch polare Gruppen an der Oberfläche der Matrix 2, jedoch mit entgegenge¬ setzter Polarität, vermittelt werden. So können bei¬ spielsweise Ionenaustauschermaterialien als Matrix 2 der erfindungsgemäßen Vorrichtung zur Trennung und Rei¬ nigung von polaren Molekülen eingesetzt werden. Weitere bevorzugte Ausgestaltungen der erfindungsgemäßen Vor¬ richtung können als Matrix 2 ein Reversed-Phase- und/ oder ein Affinitätschromatographiematerial beinhalten. Die Porengröße der porösen Chromatographiematerialien beträgt vorzugsweise 20 bis 1000 nm, und die Korngröße der Materialien insbesondere 10 bis 2000 μm, vorzugs¬ weise 75 μm bis 125 μm.The choice of the appropriate chromatography material depends on the particular molecules to be separated and purified and is known to the person skilled in the art on the basis of the rules of chromatography. For example, if a polar molecule is to be adsorbed on the matrix 2, it will only be adsorbed on the surface of the matrix 2 if there are corresponding interactions, for example likewise by polar groups on the surface of the matrix 2, but with opposite effects ¬ set polarity. For example, ion exchange materials can be used as matrix 2 of the device according to the invention for the separation and purification of polar molecules. Further preferred embodiments of the device according to the invention can contain a reversed-phase and / or an affinity chromatography material as matrix 2. The pore size of the porous chromatography materials is preferably 20 to 1000 nm, and the grain size of the materials in particular 10 to 2000 μm, preferably 75 μm to 125 μm.
Die die Matrix 2 fixierenden Einrichtungen 3a, 3b sind vorzugsweise als poröse Fritten mit Porengrößen von 10 μ bis 1 mm, vorzugsweise 70 μm bis 2000 μ ausge¬ staltet. Die porösen Fritten können aus Kunststoffen, insbeson¬ dere aus Teflon (PTFE) , Polyethylen, Polypropylen, Po¬ lystyrol, Polyurethan etc. bestehen. Aber auch anorga¬ nische Werkstoffe, wie Glas und/oder gesintertes Metall sind geeignete Materialien zur Herstellung der porösen Fritten.The devices 3a, 3b fixing the matrix 2 are preferably designed as porous frits with pore sizes of 10 μm to 1 mm, preferably 70 μm to 2000 μm. The porous frits can consist of plastics, in particular Teflon (PTFE), polyethylene, polypropylene, polystyrene, polyurethane etc. However, inorganic materials such as glass and / or sintered metal are also suitable materials for the production of the porous frits.
Die Figuren 3a und 3b zeigen eine weitere Ausgestaltung der erfindungsgemäßen Vorrichtung, deren einfache Her¬ stellung besonders vorteilhaft ist. In den Hohlkörper 1 wird eine entnehmbare Kartusche 5 eingesetzt, welche die Matrix 2 zwischen den die Matrix fixierenden Ein¬ richtungen 3a und 3b enthält. Die Einrichtung 3b ist dabei über einem netzartigen Träger 6 angeordnet, der vorzugsweise aus demselben Material wie die entnehmbare Kartusche 5 besteht. In besonders vorteilhafter Weise werden der netzartige Träger 6 und die Kartusche 5 in einem Arbeitsgang produziert, beispielsweise im Spritz¬ gußverfahren, wenn Kartuschen aus Kunststoff, insbeson¬ dere Polypropylen, hergestellt werden, über der Ma¬ trix 2 ist die Einrichtung 3a angeordnet, auf der ih¬ rerseits wiederum ein poröser, netzartiger Deckel 7 angeordnet ist. Dadurch wird die Anordnung in der ent¬ nehmbaren Kartusche 5, bestehend aus erster Einrich¬ tung 3b, Matrix 2 und zweiter Einrichtung 3a, zusätz¬ lich fixiert. Die Figur 3b zeigt die Gesamtanordnung, bestehend aus Hohlkörper 1 und entnehmbarer Kartu¬ sche 5. Diese Gesamtanordnung, bestehend aus Kartu¬ sche 5, die Matrix 2 fixierenden Einrichtungen 3a,b und Deckel 7 kann in besonders vorteilhafter Weise mit han¬ delsüblichen Pipettenspitzen kombiniert werden. Im ein¬ fachsten Fall geschieht dies durch Hineindrücken der entnehmbaren Kartusche 5 in den entsprechenden Hohlkör¬ per 1, insbesondere eine Pipettenspitze. Es versteht sich von selbst, daß die Kartusche 5 so dimensioniert ist, daß sie einen leichten Druck auf die Innenwände der Pipettenspitze ausübt, um bei Aufnahme von Flüssig¬ keit oder einer Probe nicht hochgedrückt zu werden bzw. um die notwendige Abdichtung zur Innenwand des Hohlkör¬ pers 1, vorzugsweise einer Pipettenspitze, und derFIGS. 3a and 3b show a further embodiment of the device according to the invention, the simple manufacture of which is particularly advantageous. A removable cartridge 5 is inserted into the hollow body 1 and contains the matrix 2 between the devices 3a and 3b fixing the matrix. The device 3b is arranged above a net-like carrier 6, which preferably consists of the same material as the removable cartridge 5. In a particularly advantageous manner, the net-like carrier 6 and the cartridge 5 are produced in one operation, for example in the injection molding process, if cartridges are made of plastic, in particular polypropylene, the device 3a is arranged above the matrix 2 which in turn is arranged a porous, mesh-like cover 7. As a result, the arrangement in the removable cartridge 5, consisting of the first device 3b, matrix 2 and second device 3a, is additionally fixed. FIG. 3b shows the overall arrangement, consisting of hollow body 1 and removable cartridge 5. This overall arrangement, consisting of cartridge 5, devices 3a, b and cover 7 fixing the matrix 2 can be combined in a particularly advantageous manner with commercially available pipette tips become. In the simplest case, this is done by pushing the removable cartridge 5 into the corresponding hollow body 1, in particular a pipette tip. It goes without saying that the cartridge 5 is dimensioned so that it exerts a slight pressure on the inner walls of the pipette tip in order not to be pushed up when absorbing liquid or a sample or to provide the necessary seal to the inner wall of the hollow body 1, preferably a pipette tip, and the
Außenwand der entnehmbaren Kartusche 5 zu gewährlei- sten. Die Wandstärke der entnehmbaren Kartusche 5 des netzartigen Trägers 6 und des porösen netzartigen Deckels 7 ist auf die verwendete Pipettenspitze abge¬ stimmt.To ensure the outer wall of the removable cartridge 5. The wall thickness of the removable cartridge 5 of the mesh-like carrier 6 and of the porous mesh-like cover 7 is matched to the pipette tip used.
Der Vorteil der erfindungsgemäßen Vorrichtung liegt in der praktischen Handhabung und der Art der Packung der Matrix 2, die einen Fluß der die Moleküle enthaltenden Lösung in Hin- und Rückrichtung zuläßt. Ist der kegel- stumpfför ige Hohlkörper 1 beispielsweise als Pipet¬ tenspitze ausgebildet, so wird die Pipettenspitze in die Probe eingetaucht, die Probe in der Pipettenspitze durch die Matrix 2 hindurch hochgesaugt und anschlies- send herausgedrückt. Dadurch wird eine höhere Effizienz der Adsorption erzielt, da die Probe das Chromatogra¬ phiematerial zweimal passiert. Da man mit einem ge¬ schlossenen System arbeiten kann, wird eine Kontaminie¬ rung der Probe oder eine Gefährdung der Umwelt vermie¬ den. Die erfindungs emäße Vorrichtung erleichtert die Arbeitsweise insgesamt, die bei der Trennung und Reini¬ gung von Molekülen anzuwenden ist. Insbesondere können mit Hilfe der erfindungsgemäßen Vorrichtung auch Biopo¬ lymere, insbesondere Nucleinsäuren und Proteine, schnell, einfach und sicher fraktioniert werden.The advantage of the device according to the invention lies in the practical handling and the type of packing of the matrix 2, which allows the solution containing the molecules to flow in the back and forth direction. If the frustoconical hollow body 1 is designed, for example, as a pipette tip, the pipette tip is immersed in the sample, the sample in the pipette tip is sucked up through the matrix 2 and then pressed out. This results in a higher efficiency of the adsorption, since the sample passes through the chromatographic material twice. Since it is possible to work with a closed system, contamination of the sample or danger to the environment is avoided. The device according to the invention simplifies the overall method of operation which is to be used in the separation and purification of molecules. In particular, with the aid of the device according to the invention, biopolymers, in particular nucleic acids and proteins, can also be fractionated quickly, easily and reliably.
Das erfindungsgemäße Verfahren wird in einer besonderen Ausführungsform durchgeführt mit einem als Pipettenspit- ze ausgestalteten Hohlkörper 1. Die die Moleküle ent¬ haltenden, zu trennenden und reinigenden Moleküle kön¬ nen dann mittels einer Pipette durch die Matrix 2 be¬ fördert werden. Soll die Pipettenspitze als Säulener¬ satz in herkömmlichen Verfahren eingesetzt werden, so - 1 -The method according to the invention is carried out in a special embodiment with a hollow body 1 designed as a pipette tip. The molecules containing, separating and cleaning the molecules can then be conveyed through the matrix 2 by means of a pipette. If the pipette tip is to be used as a column replacement in conventional processes, then - 1 -
kann mittels eines Silikonschlauches die Pipettenspitze auch mit einer Einwegspritze verbunden werden.the pipette tip can also be connected to a disposable syringe using a silicone tube.
Das erfindungsgemäße Verfahren ist geeignet, insbeson¬ dere Biopolymere wie Nukleinsäuren und Proteine zu trennen und zu reinigen, indem als Matrix 2 Ionenaus¬ tauscherchromatographiematerialien, wie sie in der deutschen Patentanmeldung P 36 39 949.3 vorgeschlagen werden, verwendet werden. Es handelt sich dabei um mit Anionenaustauschergruppen oberflächlich modifiziertes Chromatographiematerial auf Silicagelbasis. Befindet sich beispielsweise die Matrix 2 in einer Pipettenspit¬ ze, so saugt man die Nukleinsäure mit der Pipette durch die Matrix 2. Dabei werden unter Verwendung von Puffern niedriger Ionenstärke die langkettigen Nukleinsäuren adsorbiert. Will man die kurzkettigen Nukleinsäuren anschließend verwerten, drückt man die Lösung wieder durch die Matrix 2 hindurch und fängt sie auf. Dann können weitere Verfahrensschritte folgen. Ist man je¬ doch an der Analyse der langkettigen Nukleinsäuren in¬ teressiert, kann man nach einigen Waschschritten die langkettigen Nukleinsäuren durch Elution mit Puffern hoher Salzkonzentration (hohe Ionenstärke) wieder elu- ieren und entsprechend weiterverarbeiten.The method according to the invention is suitable, in particular, for separating and purifying biopolymers such as nucleic acids and proteins by using ion exchange chromatography materials as proposed in German patent application P 36 39 949.3 as the matrix 2. It is silica gel-based chromatography material modified on the surface with anion exchange groups. If, for example, the matrix 2 is in a pipette tip, the nucleic acid is sucked through the matrix 2 with the pipette. The long-chain nucleic acids are adsorbed using buffers of low ionic strength. If you then want to utilize the short-chain nucleic acids, you push the solution back through the matrix 2 and catch it. Then further procedural steps can follow. If, however, one is interested in the analysis of the long-chain nucleic acids, after a few washing steps the long-chain nucleic acids can be eluted again by elution with buffers of high salt concentration (high ionic strength) and processed accordingly.
Die Figur 4 zeigt ein Elutionsprofil, das bei Verwen¬ dung von Anionenaustauschermaterialien bei der Verwen¬ dung der erfindungsgemäßen Vorrichtung erhalten werden kann. Es zeigt sich, daß bei Verwendung des in der deut¬ schen Patentanmeldung P 36 39 949.3 vorgeschlagenen Materials zur Trennung von Nukleinsäuren ein Elutions¬ profil erhalten wird, durch das mit steigender Ionen¬ stärke Nukleinsäuren mit steigender Kettenlänge eluier- bar werden. So wird doppelsträngige DNS mit Basenpaaren > 500 erst bei einer Ionenstärke von 1,3 M Natriumchlo¬ rid erhalten, während einzelsträngige- DNS des Phagen M 13 schon bei 1,1 M Natriumchlorid eluiert wird. Die Elutionspeaks sind so scharf, daß sogar "baseline"- Trennungen möglich sind. Bei einer mittleren Ionenstär¬ ke zwischen 0,5 und 1 M Natriumchlorid eluieren Nukle¬ insäuren wie tRNS, 5S RNS und mRNS. Bei niedrigen Ionen- stärken von 0,1 bis 0,5 werden bereits Polysaccharide,FIG. 4 shows an elution profile which can be obtained when anion exchange materials are used when using the device according to the invention. It has been shown that when using the material proposed for the separation of nucleic acids in German patent application P 36 39 949.3, an elution profile is obtained by means of which nucleic acids with increasing chain length can be eluted with increasing ionic strength. Thus, double-stranded DNA with base pairs> 500 is only obtained with an ionic strength of 1.3 M sodium chloride, while single-stranded DNA of the phage M 13 is eluted at 1.1 M sodium chloride. The elution peaks are so sharp that even "baseline" separations are possible. At an average ionic strength between 0.5 and 1 M sodium chloride, nucleic acids such as tRNA, 5 RNA and mRNA elute. At low ionic strengths of 0.1 to 0.5, polysaccharides,
Proteine, Metaboliten, Farbstoffe, einzelne Nukleotide,Proteins, metabolites, dyes, individual nucleotides,
Proteine wie BSA (bovine serum albumin) und kleinereProteins such as BSA (bovine serum albumin) and smaller ones
Nukleotide wie beispielsweise ein Nukleotid Decamer, das als "linker" verwendet wird, eluiert.Nucleotides such as a nucleotide decamer used as a "left" elute.
Eine Verfahrensvariante besteht darin, als Matrix 2 ein Affinitätsadsorbens, wie es beispielsweise in der deut¬ schen Patentanmeldung P 36 27 063 vorgeschlagen wird, zu verwenden. Die Durchführung des Verfahrens erfolgt analog zur oben beschriebenen Verfahrensweise.A variant of the method consists in using an affinity adsorbent as matrix 2, as is proposed, for example, in German patent application P 36 27 063. The procedure is carried out analogously to the procedure described above.
Das erfindungsgemäße Verfahren gewährleistet die fol¬ genden Vorteile, insbesondere bei molekularbiologischen Operationen:The method according to the invention ensures the following advantages, in particular in molecular biological operations:
- Durchführung von DNS-Präparationen in sogenannten "minipreps",- performing DNA preparations in so-called "minipreps",
- Reinigung von RNS, rRNS, viraler RNS und RNS-Tran- skripten,- purification of RNA, rRNA, viral RNA and RNA transcripts,
- Reinigung von Proben, die nach Nicktranslation, End¬ markierung oder 01igonukleotid-induzierter Markie¬ rung (Oligolabeling) erhalten werden,Cleaning of samples obtained after nick translation, end labeling or oligonucleotide-induced labeling (oligolabeling),
- Entfernung der DNS-linker in Klonierungsexperimen- ten,Removal of the DNA linker in cloning experiments,
- Reinigung von Nukleinsäuren nach Gelextraktion sowie schnelle Reinigung von Nukleinsäuren nach Abdauung mit Rest-riktionsenzymen, Phosphatasebehandlungen, Polymerasereaktionen usw. anstelle einer zeitaufwen¬ digen Phenolbehandlung. Die bei Verwendung der erfindungsgemäßen Vorrichtung erhältliche Reinheit in Routinepräparationen ist zumin¬ dest mit durch Caesiu chlorid-Dichtegradienten-Zentri- fugation erhaltenen Proben vergleichbar. Die isolierten Nukleinsäuren sind befreit von Proteinen, Polysacchari- den und anderen Zell etaboliten und zeigen keinerlei Inhibierung von Enzymen bei enzymatischen Reaktionen. Die erfindungsgemäße Vorrichtung kann zur Isolierung und Reinigung von Nukleinsäuren aus Oligonukleotiden bis hin zu Plasmiden verwendet werden, wobei der Zeit¬ aufwand auf Bruchteile im Vergleich zu anderen Verfah¬ ren eingeschränkt wird.- Purification of nucleic acids after gel extraction as well as rapid purification of nucleic acids after digestion with residual restriction enzymes, phosphatase treatments, polymerase reactions etc. instead of a time-consuming phenol treatment. The purity in routine preparations obtainable when using the device according to the invention is at least comparable to samples obtained by Caesiu chloride density gradient centrifugation. The isolated nucleic acids are free of proteins, polysaccharides and other cell metabolites and show no inhibition of enzymes in enzymatic reactions. The device according to the invention can be used for the isolation and purification of nucleic acids from oligonucleotides to plasmids, the time expenditure being restricted to fractions in comparison to other processes.
Die erfindungsgemäße Vorrichtung ist geeignet zur Ver¬ wendung in einem Trennungs- und Reinigungsverfahren für Moleküle, vorzugsweise Biopolymere wie Proteine und/ oder Nukleinsäuren, insbesondere von anderen Zellbe¬ standteilen.The device according to the invention is suitable for use in a separation and purification process for molecules, preferably biopolymers such as proteins and / or nucleic acids, in particular of other cell components.
Die Verwendung der erfindungsgemäßen Vorrichtung in verschiedenen Verfahren wird in den folgenden Beispie¬ len näher erläutert. Dabei wird die erfindungsgemäße Vorrichtung in einer bevorzugten Ausführungsform, der Pipettenspitze, eingesetzt.The use of the device according to the invention in various processes is explained in more detail in the following examples. The device according to the invention is used in a preferred embodiment, the pipette tip.
B e i s p i e l 1Example 1
In eine 1 ml Pipettenspitze, passend für Gilson Pipet- an, wird eine 70 μ Polyethylen-Fritte mit 4 mm Durch¬ messer, Dicke 1,6 mm, eingeführt und durch Drücken festgeklemmt. Danach werden ca. 70 mg des Chromatogra¬ phiematerials, vorgeschlagen in der deutschen Patentan¬ meldung P 36 39 949, trocken eingefüllt. Das Chromato¬ graphiematerial wird mit einer wie oben beschriebenen Fritte mit 5,7 mm Durchmesser verschlossen und die Frit- te durch Festdrücken an ihrem Platz fixiert. Analog verfährt man bei 200 μl fassenden Pipettenspit¬ zen bzw. 5000 μl fassenden Pipettenspitzen.A 70 μ polyethylene frit with a 4 mm diameter and a thickness of 1.6 mm is introduced into a 1 ml pipette tip, suitable for Gilson Pipetan, and clamped by pressing. Then about 70 mg of the chromatographic material, proposed in German patent application P 36 39 949, are filled in dry. The chromatographic material is closed with a 5.7 mm diameter frit as described above and the frit is fixed in place by pressing. The procedure is analogous for 200 μl pipette tips or 5000 μl pipette tips.
B e i s p i e l 2Example: 2
Die allgemeine Handhabung der in Beispiel 1 hergestell¬ ten Pipettenspitze geschieht wie folgt:The general handling of the pipette tip produced in Example 1 is as follows:
Zunächst wird die Pipettenspitze einmal mit 100 μl ei¬ nes geeigneten Adsorptionspuffers äquilibriert. Bei einem zu verarbeitenden Probenvolumen von 100 bis 200 μl reicht es aus, die Probe etwa fünfmal durch das Chromatographiematerial zu drücken. Soll jedoch eine größere Flüssigkeitsmenge verarbeitet werden, wie sie beispielsweise nach Gelelution anfällt, kann die Probe mittels eines Silikonschlauches, der die Pipettenspitze und eine Einwegspritze verbindet, durch die Matrix hin¬ durchgezogen werden. Es ist dann ausreichend, daß die Probe nur zweimal das Chromatographiematerial passiert. Dabei sollte die Fließgeschwindigkeit der Lösung nicht höher als 1 ml pro Minute sein.First, the pipette tip is equilibrated once with 100 μl of a suitable adsorption buffer. With a sample volume of 100 to 200 μl to be processed, it is sufficient to push the sample through the chromatography material about five times. However, if a larger amount of liquid is to be processed, such as is obtained after gel elution, the sample can be drawn through the matrix using a silicone tube that connects the pipette tip and a disposable syringe. It is then sufficient for the sample to pass the chromatography material only twice. The flow rate of the solution should not be higher than 1 ml per minute.
Als Äguilibrierungs- und Adsorptionspuffer kann der Puffer A verwendet werden. Puffer A:Buffer A can be used as equilibration and adsorption buffer. Buffer A:
400 mM Natriumchlorid 15% Ethanol 50 mM MOPS (3-N-Morphdlinopropansulfonsäure) 1 mM EDTA (Ethylendiamintetraacetat) pH 7.0400 mM sodium chloride 15% ethanol 50 mM MOPS (3-N-morphine linopropanesulfonic acid) 1 mM EDTA (ethylenediaminetetraacetate) pH 7.0
Analog zum oben beschriebenen Adsorptionsvorgang werden die Waschschritte durchgeführt. Als Waschpuffer dienen bei Nukleinsäurepräparationen typischerweise die Puffer B, C und D. Puffer B : Puffer C:The washing steps are carried out analogously to the adsorption process described above. In nucleic acid preparations, buffers B, C and D are typically used as washing buffers. Buffer B: Buffer C:
750 mM Natriumchlorid 1000 mM Natriumchlorid 15% Ethanol 15% Ethanol 50 mM MOPS 50 mM MOPS 1 M EDTA 1 mM EDTA pH 7.0 pH 7.0750 mM sodium chloride 1000 mM sodium chloride 15% ethanol 15% ethanol 50 mM MOPS 50 mM MOPS 1 M EDTA 1 mM EDTA pH 7.0 pH 7.0
Puffer D:Buffer D:
1000 mM Natriumchlorid 50 mM MOPS pH 7.01000 mM sodium chloride 50 mM MOPS pH 7.0
Man füllt ein Eppendorf-Gefäß mit 1 ml Waschpuffer und spült dreimal 150 μl durch das Chromatographiematerial, um Verunreinigungen zu entfernen. Dieser Schritt wird wiederholt.An Eppendorf tube is filled with 1 ml of washing buffer and 150 μl are rinsed three times through the chromatography material in order to remove impurities. This step is repeated.
Die Elution der adsorbierten Nukleinsäuren erfolgt wie in beiden vorgangegangenen Schritten entweder mit einer Eppendorf- oder Gilson-Pipette oder mit einer Einweg¬ spritze, wobei darauf zu achten ist, daß die Pipetten¬ spitze mittels eines Silikonschlauches mit der Einweg¬ spritze verbunden ist. Es wird einfach der Elutionspuf- fer E oder FAs in the two preceding steps, the adsorbed nucleic acids are eluted either with an Eppendorf or Gilson pipette or with a disposable syringe, care being taken that the pipette tip is connected to the disposable syringe by means of a silicone tube. It simply becomes the elution buffer E or F
Puffer E: Puffer F:Buffer E: Buffer F:
1100 mM Natriumchlorid 1500 mM Natriumchlorid 15% Ethanol 15% Ethanol 4 M Urea 50 mM MOPS 50 M MOPS 1 mM EDTA 1 mM EDTA pH 7.50 pH 7.01100 mM sodium chloride 1500 mM sodium chloride 15% ethanol 15% ethanol 4 M urea 50 mM MOPS 50 M MOPS 1 mM EDTA 1 mM EDTA pH 7.50 pH 7.0
durch die Pipettenspitze gesaugt bzw. gedrückt. Dieser Schritt wird einmal wiederholt. Die Eluate werden ver¬ einigt und die Nukleinsäure daraus gefällt. B e i s p i e l 3sucked or pressed through the pipette tip. This step is repeated once. The eluates are combined and the nucleic acid is precipitated therefrom. Example 3
Eine Pipettenspitze, hergestellt nach Beispiel 1, wird mit 50 mM Natriumphosphatpuffer hydratisiert und äqui- libriert, indem man 750 μl Puffer mehrmals durch dieA pipette tip, produced according to Example 1, is hydrated with 50 mM sodium phosphate buffer and equilibrated by passing 750 μl buffer several times through the
Pipette saugt. Ei.ne Probe, di.e 20 μg Plasmi.d pBR322 DNS in 500 μl 0,5 M Natriumchlorid und 50 mM Natriumphos¬ phat, pH 7, enthält, wird an das Chromatographiemate¬ rial durch fünfmaliges Hochsaugen und Ausdrücken adsor¬ biert. Nicht gebundene Bestandteile und Verunreinigun¬ gen werden durch fünfmaliges Hochsaugen und Ausdrücken von jeweils 1 ml frischem 0,5 M Natriumchlorid und 50 mM Natriumphosphat, pH 7, ausgewaschen. Die Plasmid- DNS wird anschließend mit 1,5 M Natriumchlorid und 50 mM Natriumphosphat, pH 7, eluiert, indem man 1 ml des Elutionspuffers dreimal hochsaugt und ausdrückt.Pipette sucks. A sample containing 20 μg of Plasmid pBR322 DNA in 500 μl of 0.5 M sodium chloride and 50 mM sodium phosphate, pH 7, is adsorbed onto the chromatography material by sucking it up five times and pressing it out. Unbound constituents and impurities are washed out five times by sucking up and squeezing out 1 ml of fresh 0.5 M sodium chloride and 50 mM sodium phosphate, pH 7. The plasmid DNA is then eluted with 1.5 M sodium chloride and 50 mM sodium phosphate, pH 7, by sucking up 1 ml of the elution buffer three times and squeezing it out.
B e i s p i e l 4Example 4
Eine Plas id-DNS-Probe wird in einer sogenannten Mini¬ präparation typischerweise durch folgende Schritte ge¬ wonnen:A plasmid DNA sample is typically obtained in a so-called mini-preparation by the following steps:
Die Bakterienzellen werden über Nacht inkubiert und am nächsten Tag durch Zentrifugation geerntet. Das Pellet wird in 85 μl einer eiskalten Lösung von 50 mM Tris- HC1, pH 7.4, mit 2 mg/ml Lysozym (frisch zubereitet) aufgeschlossen und 10 Minuten auf Eis inkubiert. Danach werden 20 μl einer 0.5 M EDTA-Lösung hinzugefügt und weitere 10 Minuten inkubiert. Nach Zugabe von 4 μl 2%- igem Triton X' 100 inkubiert man auf Eis für eine wei¬ tere Stunde. Die Probe wird in einer Laborzentrifuge 30 Minuten bei maximaler Drehzahl zentrifugiert, und 100 μl des von Zelltrümmern befreiten Zell-Lysates wer¬ den in ein anderes Eppendorf-Gefäß überführt, wonach 1 Volumen 2 M Natriumchlorid, 100 mM MOPS, pH 7, und 5 μl Isoa ylalkohol zugegeben werden. Eine erfindungsgemäße Pipettenspitze der Firma Gilson, Brand, Eppendorf, her¬ gestellt nach Beispiel 1, wird mit 100 μl Puffer C äqui- libriert. Danach adsorbiert man 100 μl einer E. coli- Plasmid-DNS-Probe an dem Chromatographiematerial, indem man die Probe fünfmal auf- und abpipettiert. Nach der Adsorption wird mit insgesamt 2 bis 5 ml des Puffers C gewaschen, woraufhin die Plasmid-DNS mittels 300 μl des Puffers F eluiert wird. Anschließend fällt man die DNS mit 300 μl Isopropanol, läßt 15 Minuten stehen und zen- trifugiert dann die Probe dann in einer Eppendorf-Labor¬ zentrifuge 30 Minuten lang.The bacterial cells are incubated overnight and harvested the next day by centrifugation. The pellet is disrupted in 85 μl of an ice-cold solution of 50 mM Tris-HCl, pH 7.4, with 2 mg / ml lysozyme (freshly prepared) and incubated on ice for 10 minutes. Then 20 μl of a 0.5 M EDTA solution are added and incubated for a further 10 minutes. After adding 4 μl of 2% Triton X '100, the mixture is incubated on ice for a further hour. The sample is centrifuged in a laboratory centrifuge for 30 minutes at maximum speed, and 100 μl of the cell lysate freed from cell debris are transferred to another Eppendorf tube, after which 1 volume of 2 M sodium chloride, 100 mM MOPS, pH 7 and 5 μl Isoa yl alcohol can be added. A pipette tip according to the invention from Gilson, Brand, Eppendorf, manufactured according to Example 1, is equilibrated with 100 μl buffer C. Then 100 μl of an E. coli plasmid DNA sample is adsorbed on the chromatography material by pipetting the sample up and down five times. After adsorption, washing is carried out with a total of 2 to 5 ml of buffer C, whereupon the plasmid DNA is eluted using 300 μl of buffer F. The DNA is then precipitated with 300 μl of isopropanol, left to stand for 15 minutes and then the sample is centrifuged in an Eppendorf laboratory centrifuge for 30 minutes.
B e i s p i e l 5Example 5
Die Isolierung von mRNS, rRNS und viraler RNS von Roh¬ extrakten geschieht wie folgt:The isolation of mRNA, rRNA and viral RNA from crude extracts takes place as follows:
Der RNS-Extrakt wird mit Ethanol gefällt und das erhal¬ tene Pellet in TE-Puffer (10 mM Tris/1 mM EDTA, pH 7.5) resuspendiert. Man stellt die Adsorptionsbedingungen durch Zugabe von 0.1 Volumenteil (bezogen auf die re¬ suspendierte Lösung) 5 M Natriumchlorid und 0,2 Volu¬ menteile 250 mM MOPS, pH 7.0 ein. Die Pipettenspitze wird mit 1 μl Puffer A äquilibriert. Danach wird die Probe durch fünfmaliges Auf- und Abpipettieren an das Chromatographiematerial adsorbiert. Man spült mit Puf¬ fer A, um Verunreinigungen zu eliminieren. Die Elution erfolgt mit 300 μl des Puffers C. Die RNS wird durch Zugabe von 2,5 Volumenteilen Ethanol gefällt. Nach Ste¬ henlassen bei -20°C, 30 Minuten, wird in einer Eppen¬ dorf-Zentrifuge insgesamt 30 Minuten bei höchster Dreh¬ zahl zentrifugiert. Das Pellet wird vor der Weiterver¬ arbeitung sorgfältig mit Ethanol gewaschen. Die Probe soll einen Nukleinsäuregehalt von höchstens 15 μg ha¬ ben. B e i s p i e l 6The RNA extract is precipitated with ethanol and the pellet obtained is resuspended in TE buffer (10 mM Tris / 1 mM EDTA, pH 7.5). The adsorption conditions are adjusted by adding 0.1 part by volume (based on the re-suspended solution) of 5 M sodium chloride and 0.2 part by volume of 250 mM MOPS, pH 7.0. The pipette tip is equilibrated with 1 μl buffer A. The sample is then adsorbed onto the chromatography material by pipetting up and down five times. One rinses with buffer A in order to eliminate impurities. Elution is carried out with 300 μl of buffer C. The RNA is precipitated by adding 2.5 parts by volume of ethanol. After standing at -20 ° C. for 30 minutes, centrifugation in an Eppendorf centrifuge takes a total of 30 minutes at the highest speed. The pellet is carefully washed with ethanol before further processing. The sample should have a nucleic acid content of at most 15 μg. Example 6
Reinigung von mRNS zur Synthese der entsprechenden cDNS wird wie in Beispiel 5 beschrieben durchgeführt.Purification of mRNA for the synthesis of the corresponding cDNA is carried out as described in Example 5.
B e i s p i e l 7Example 7
Nicht verbrauchte Triphosphate in Markierungsreaktionen wie Nicktranslationen, Endmarkierungen und Oligonukleo- tid-abhängigen Markierungen (Oligolabeling) von DNS werden wie folgt entfernt:Unused triphosphates in labeling reactions such as nick translations, end labels and oligonucleotide-dependent labels (oligolabeling) of DNA are removed as follows:
Die Markierungsreaktion der DNS wird durch Zugabe von 2 μl 0,5 M EDTA pro 20 μl Probenvolumen beendet, und man stellt die Adsorptionsbedingungen durch Zugabe von 1 Volumenteil des Puffers C ein. Die Gesamtsalz-Endkon¬ zentration soll in etwa 500 mM betragen. Die Pipetten¬ spitze gemäß der Erfindung wird mit 100 μl Puffer B äguilibriert. Die Probe wird durch fünfmaliges Hochsau¬ gen und Ausdrücken an das Chromatographiematerial ad¬ sorbiert und insgesamt mit 10 ml des Puffers B gewa¬ schen, um die nicht reagierten Nukleotide abzutrennen. Die Fließgeschwindigkeit des Waschpuffers soll vorzugs¬ weise ca. 5 ml pro Minute betragen. Die markierte DNS wird anschließend mit insgesamt 300 μl des Puffers F eluiert. Die Probe kann direkt weiterverwendet werden, wenn sie mit dem zur Hybridisierung vorgesehenen Puffer mindestens 1:20 verdünnt wird. Anderenfalls wird die Probe ausgefällt und in TE-Puffer gelöst.The labeling reaction of the DNA is terminated by adding 2 μl 0.5 M EDTA per 20 μl sample volume, and the adsorption conditions are adjusted by adding 1 volume part of the buffer C. The total final salt concentration should be approximately 500 mM. The pipette tip according to the invention is equilibrated with 100 μl buffer B. The sample is adsorbed onto the chromatography material by suction up five times and squeezed out and washed with a total of 10 ml of buffer B in order to separate the unreacted nucleotides. The flow rate of the washing buffer should preferably be approximately 5 ml per minute. The labeled DNA is then eluted with a total of 300 μl of the buffer F. The sample can be used directly if it is diluted at least 1:20 with the buffer intended for hybridization. Otherwise the sample is precipitated and dissolved in TE buffer.
B e i s p i e l 8Example 8
Die Entfernung eines DNS-linkers von einer DNS mit mehr als ca. 400 Basenpaaren in einem Klonierungsexperiment wird wie folgt durchgeführt: Die zu reinigende Probe wird mit 1 Volumenteil des Puf¬ fers C verdünnt, damit die Endkonzentration an Salz ungefähr 500 mM beträgt. Die erfindungsgemäße Pipetten¬ spitze wird mit 100 μl des Puffers A äquilibriert. Die Probe wird wie in den vorhergehenden Beispielen adsor¬ biert. Die erfindungsgemäße Pipettenspitze wird mit Puffer B gespült, um die Verunreinigungen zu entfernen. Die DNS wird desorbiert und eluiert mit insgesamt 300 μl des Puffers F. Anschließend isoliert man die DNS durch Isopropanolfällung (Zugabe von 1 Volumenteil) und läßt 15 Minuten auf Eis stehen, wonach sich eine Zen- trifugation der Probe in einer Eppendorf-Zentrifuge für die Dauer von 30 Minuten anschließt. Danach wäscht man sorgfältig mit 70%-igem Ethanol.The removal of a DNA linker from a DNA with more than approx. 400 base pairs in a cloning experiment is carried out as follows: The sample to be cleaned is diluted with 1 part by volume of the buffer C so that the final concentration of salt is approximately 500 mM. The pipette tip according to the invention is equilibrated with 100 μl of buffer A. The sample is adsorbed as in the previous examples. The pipette tip according to the invention is rinsed with buffer B in order to remove the contaminants. The DNA is desorbed and eluted with a total of 300 μl of buffer F. Then the DNA is isolated by isopropanol precipitation (addition of 1 part by volume) and left on ice for 15 minutes, after which the sample is centrifuged in an Eppendorf centrifuge for the Duration of 30 minutes. Then wash carefully with 70% ethanol.
B e i s p i e l 9Example: 9
Die Schnellreinigung einer DNS-Probe nach enzymatischer Modifizierung (zum Beispiel durch Phosphatase, Restrik- tionsendonuklease, Poly erasen usw. sowie Cofaktoren) erreicht man gemäß folgender Verfahrensweise:The rapid cleaning of a DNA sample after enzymatic modification (for example by phosphatase, restriction endonuclease, poly erases, etc., and cofactors) is achieved using the following procedure:
Das zugrunde liegende Reaktionsvolumen beträgt 50 μl und enthält nicht mehr als 100 mM Natriumchlorid. 5 μl 0,5 M EDTA, pH 8.0, werden zum Reaktionsvolumen hinzu¬ gefügt, um die Modifizierungsreaktion abzubrechen. Ein Volumenteil des Puffers C wird zugegeben, um die Adsorp¬ tionsbedingungen einzustellen mit einer Salzkonzentra¬ tion von etwa 500 mM. Die erfindungsgemäße Pipetten¬ spitze wird äquilibriert, die Probe wird adsorbiert und anschließend eluiert wie in Beispiel 8 beschrieben. Auch die weitere Behandlung der Probe geschieht wie in Beispiel 8 beschrieben. B e i s p i e l 1 0The underlying reaction volume is 50 μl and contains no more than 100 mM sodium chloride. 5 μl of 0.5 M EDTA, pH 8.0, are added to the reaction volume in order to terminate the modification reaction. A volume part of the buffer C is added in order to set the adsorption conditions with a salt concentration of about 500 mM. The pipette tip according to the invention is equilibrated, the sample is adsorbed and then eluted as described in Example 8. The further treatment of the sample is also carried out as described in Example 8. Example 1 0
Die erfindungsgemäße Vorrichtung kann auch dazu benutzt werden, um Agarose- und Acrylamid-Verunreinigungen ef¬ fizient abzutrennen. Dies ist insbesondere dann erfor- derlich, wenn Gelelutionen der Probe stattgefunden ha¬ ben. Bei Anwendung der im folgenden beschriebenen Ver¬ fahrensweise wird die DNS gleichzeitig konzentriert, selbst wenn das Startvolumen einige ml beträgt. Die DNS hat eine Größe von > 400 Basenpaaren und kann in einer Menge von 5 ng bis 15 μg vorliegen. Die Probenvorberei¬ tung und die Äquilibrierung der erfindungsgemäßen Pi¬ pettenspitze wird wie in Beispiel 8 beschrieben durch¬ geführt. Dann überführt man die Probe in eine Einweg¬ spritze und drückt sie zweimal durch die erfindungsge¬ mäße Pipettenspitze. Dabei soll die Fließgeschwindig- keit bei etwa 250 μl/ in liegen. Die erfindungsgemäße Pipettenspitze wird anschließend mit 5 ml des Puffers B gewaschen bei einer Durchflußgeschwindigkeit von 5 ml/min. Die Weiterbehandlung der DNS-Probe geschieht wie in Beispiel 8 beschrieben. The device according to the invention can also be used to efficiently separate agarose and acrylamide impurities. This is particularly necessary when gel elution of the sample has taken place. When using the procedure described below, the DNA is concentrated at the same time, even if the starting volume is a few ml. The DNA has a size of> 400 base pairs and can be present in an amount from 5 ng to 15 μg. The sample preparation and the equilibration of the pipette tip according to the invention is carried out as described in Example 8. The sample is then transferred to a disposable syringe and pressed twice through the pipette tip according to the invention. The flow rate should be around 250 μl / in. The pipette tip according to the invention is then washed with 5 ml of buffer B at a flow rate of 5 ml / min. The further treatment of the DNA sample is carried out as described in Example 8.

Claims

- 37 -P a t e n t a n s p r ü c h e - 37-patent claims
1. Vorrichtung zur Trennung und Reinigung von Molekülen aus einer Lösung durch Adsorption der Moleküle an einer Matrix, dadurch gekennzeichnet, daß die Matrix (2) in einem an beiden Enden (4a, 4b) offenen, kegelstumpfför¬ migen Hohlkörper (1) , an den gegebenenfalls an der wei¬ teren Öffnung (4a) ein zylindrischer Hohlkörper an¬ schließt, zwischen zwei für die Lösung durchlässigen Einrichtungen (3a, 3b) angeordnet ist, wobei die Matrix (2) und die Einrichtungen (3a, 3b) zusammen 5 bis 50 % des Hohlkörpervolumens ausfüllen und die weitere Öff¬ nung (4a) des kegelstumpfförmigen Hohlkörpers (1) an eine Pipette anschließbar ist.1. Device for the separation and purification of molecules from a solution by adsorption of the molecules on a matrix, characterized in that the matrix (2) in an open at both ends (4a, 4b), truncated cone-shaped hollow body (1) which is optionally connected to the further opening (4a) by a cylindrical hollow body, is arranged between two devices (3a, 3b) which are permeable to the solution, the matrix (2) and the devices (3a, 3b) altogether 5 to Fill 50% of the hollow body volume and the further opening (4a) of the frustoconical hollow body (1) can be connected to a pipette.
2. Vorrichtung nach Anspruch 1, dadurch gekennzeichnet, daß der Hohlkörper (1) eine Pipettenspitze ist.2. Device according to claim 1, characterized in that the hollow body (1) is a pipette tip.
3. Vorrichtung nach einem der Ansprüche 1 oder 2, dadurch gekennzeichnet, daß die Einrichtungen (3a, 3b) die Ma¬ trix (2) im Hohlkörper (1) fixieren.3. Device according to one of claims 1 or 2, characterized in that the devices (3a, 3b) fix the Ma¬ trix (2) in the hollow body (1).
4. Vorrichtung nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß zwischen der engeren Öffnung (4b) und der unteren Einrichtung (3b) ein freier Raum ist.4. Device according to one of claims 1 to 3, characterized in that between the narrower opening (4b) and the lower device (3b) is a free space.
5. Vorrichtung nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß in dem Hohlkörper (1) eine entnehm¬ bare Kartusche (5) angeordnet ist, die die zur Trennung und Reinigung dienende Matrix (2) zwischen zwei Ein¬ richtungen (3a,b) fixiert, wobei die Einrichtung (3b) über einem netzartigen Träger (6) angeordnet ist, die entnehmbare Kartusche von einem porösen netzartigen Deckel (7) verschlossen ist, wobei der Deckel (7) über der Einrichtung (3a) angeordnet ist und die entnehmbare Kartusche (5) an der Innenwandung des Hohlkörpers (1) dicht abschließt. 5. Device according to one of claims 1 to 4, characterized in that in the hollow body (1) a removable cartridge (5) is arranged, which is used for separation and cleaning matrix (2) between two devices (3a , b) fixed, the device (3b) being arranged above a net-like carrier (6), the removable cartridge being closed by a porous net-like cover (7), the lid (7) being arranged above the device (3a) and the removable cartridge (5) on the inner wall of the hollow body (1) closes tightly.
6. Vorrichtung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß die entnehmbare Kartusche (5) , der netzartige Träger (6) und der poröse netzartige Deckel (7) aus demselben Material bestehen.6. Device according to one of claims 1 to 5, characterized in that the removable cartridge (5), the mesh-like carrier (6) and the porous mesh-like cover (7) consist of the same material.
7. Vorrichtung nach Anspruch 6, dadurch gekennzeichnet, daß das Material aus Kunststoffen wie Teflon (PTFE) , Polyethylen, Polypropylen, Polystyrol und/oder Polyure- tan ist.7. The device according to claim 6, characterized in that the material is made of plastics such as Teflon (PTFE), polyethylene, polypropylene, polystyrene and / or polyurethane.
8. Vorrichtung nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß die Matrix aus porösem Chromatogra¬ phiematerial auf der Basis von Silicagel, Aluminium¬ oxid, Titandioxid, Hydroxylapatit, Dextran, Agarose, Acrylamid, Polystyrol, Polyvinylalkohol oder anderen organischen Polymeren, Derivaten oder aus Copolymeren der oben genannten Trägermaterialien besteht.8. Device according to one of claims 1 to 7, characterized in that the matrix of porous Chromatogra¬ phiematerial based on silica gel, aluminum oxide, titanium dioxide, hydroxylapatite, dextran, agarose, acrylamide, polystyrene, polyvinyl alcohol or other organic polymers, Derivatives or copolymers of the above-mentioned carrier materials.
9. Vorrichtung nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, daß die Matrix ein oberflächlich modi¬ fiziertes Chromatographiematerial aus Silicagel, Alumi¬ niumdioxid, Titandioxid, Hydroxylapatit, Dextran, Aga¬ rose, Acrylamid, Polystyrol, Polyvinylalkohol oder an¬ deren organischen Polymeren, Derivaten oder aus Copoly¬ meren der oben genannten Trägermaterialien ist.9. Device according to one of claims 1 to 8, characterized in that the matrix is a superficially modified chromatography material made of silica gel, aluminum oxide, titanium dioxide, hydroxyapatite, dextran, agarose, acrylamide, polystyrene, polyvinyl alcohol or other organic Polymers, derivatives or copolymers of the above-mentioned carrier materials.
10. Vorrichtung nach Anspruch 9, dadurch gekennzeichnet, daß das oberflächlich modifizierte Chromatographiemate¬ rial ein Ionenaustauscher, ein Reversed-Phase- und/oder ein Affinitätschromatographiematerial ist.10. The device according to claim 9, characterized in that the surface modified Chromatographiemate¬ rial is an ion exchanger, a reversed phase and / or an affinity chromatography material.
11. Vorrichtung nach einem der Ansprüche 1 bis 10, dadurch gekennzeichnet, daß die Porengröße der porösen Chroma¬ tographiematerialien 20 bis 1000 nm und die Korngröße der Materialien 10 bis 2000 μ , vorzugsweise 75 bis 125 μm beträgt. - ±9 -11. Device according to one of claims 1 to 10, characterized in that the pore size of the porous Chroma¬ tographiematerialien 20 to 1000 nm and the grain size of the materials is 10 to 2000 microns, preferably 75 to 125 microns. - ± 9 -
12. Vorrichtung nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, daß die die Matrix fixierenden Einrich¬ tungen (3a, 3b) poröse Fritten sind mit Porengrößen von 10 μm bis 1 mm, vorzugsweise 70 bis 200 μm.12. Device according to one of claims 1 to 11, characterized in that the matrix-fixing devices (3a, 3b) are porous frits with pore sizes of 10 μm to 1 mm, preferably 70 to 200 μm.
13. Verfahren zur Trennung und Reinigung von Molekülen aus einer Lösung durch Adsorption der Moleküle an eine Ma¬ trix mittels einer Vorrichtung, in der die die zu tren¬ nenden Moleküle enthaltende Lösung durch eine in einem Hohlkörper angeordnete Matrix hindurchgedrückt wird, dadurch gekennzeichnet, daß die Matrix (2) von einer oberen und einer unteren Einrichtung (3a, 3b) fixiert wird und daß die Lösung durch die Matrix (2) hindurch in einen oberhalb der oberen Einrichtung (3a) vorhande¬ nen freien Raum gesogen wird und anschließend durch die Matrix (2) hindurch aus dem Hohlkörper (1) gedrückt wird.13. A method for separating and purifying molecules from a solution by adsorbing the molecules onto a matrix by means of a device in which the solution containing the molecules to be separated is pressed through a matrix arranged in a hollow body, characterized in that the matrix (2) is fixed by an upper and a lower device (3a, 3b) and that the solution is drawn through the matrix (2) into a free space above the upper device (3a) and then through the Matrix (2) is pressed out of the hollow body (1).
14. Verfahren nach Anspruch 13, dadurch gekennzeichnet, daß Biopolymere getrennt und gereinigt werden.14. The method according to claim 13, characterized in that biopolymers are separated and purified.
15. Verfahren nach Anspruch 14, dadurch gekennzeichnet, daß Nukleinsäuren und/oder Proteine getrennt und gereinigt werden.15. The method according to claim 14, characterized in that nucleic acids and / or proteins are separated and purified.
16. Verwendung einer Vorrichtung nach einem der Ansprüche 1 bis 12 zur Trennung und Reinigung von Molekülen, vor¬ zugsweise Biopolymeren.16. Use of a device according to one of claims 1 to 12 for the separation and purification of molecules, preferably biopolymers.
17. Verwendung einer Vorrichtung nach Anspruch 16 zur Tren¬ nung und Reinigung von Proteinen und/oder Nukleinsäu¬ ren. 17. Use of a device according to claim 16 for the separation and purification of proteins and / or nucleic acids.
PCT/EP1988/000442 1987-05-22 1988-05-19 Process and device for separating and cleaning molecules WO1988009201A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3717211.5 1987-05-22
DE19873717211 DE3717211A1 (en) 1987-05-22 1987-05-22 DEVICE AND METHOD FOR SEPARATING AND CLEANING MOLECULES

Publications (1)

Publication Number Publication Date
WO1988009201A1 true WO1988009201A1 (en) 1988-12-01

Family

ID=6328135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1988/000442 WO1988009201A1 (en) 1987-05-22 1988-05-19 Process and device for separating and cleaning molecules

Country Status (2)

Country Link
DE (1) DE3717211A1 (en)
WO (1) WO1988009201A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003374A2 (en) * 1991-07-26 1993-02-18 Friedrich-Schiller-Universität Jena Method and apparatus for the analysis of agglutination reactions
WO1993019368A1 (en) * 1992-03-18 1993-09-30 Abion Ohg Dr. Erhardt U. Maier One-way reaction vessel for the solid-phase immunological analysis of, and a method of measuring constituents which can be determined via immune reactions
EP0587951A1 (en) * 1992-09-18 1994-03-23 AMERSHAM INTERNATIONAL plc Cell nuclei capture method and device used therefor
EP0688426A1 (en) * 1993-03-08 1995-12-27 WAINWRIGHT, Norman Aligned fiber diagnostic chromatography
EP0691148A2 (en) * 1991-04-03 1996-01-10 The Perkin-Elmer Corporation A method for separating double stranded DNA from single stranded DNA or RNA
US5556598A (en) * 1992-09-18 1996-09-17 Amersham International Plc. Device and method for affinity separation
DE19806780C1 (en) * 1998-02-18 1999-07-01 November Ag Molekulare Medizin Apparatus to isolate and purify nucleic acids
EP1015098A1 (en) * 1997-02-26 2000-07-05 Millipore Corporation Cast membrane structures for sample preparation
EP1362126A2 (en) * 2001-01-17 2003-11-19 Kemmons A. Tubbs An integrated high throughput system for the analysis of biomolecules
EP1485179A1 (en) * 2002-03-19 2004-12-15 Waters Investments Limited Device for solid phase extraction and method for purifying samples prior to analysis
US6998047B1 (en) 1997-02-26 2006-02-14 Millipore Corporation Cast membrane structures for sample preparation
US7163660B2 (en) 2000-05-31 2007-01-16 Infineon Technologies Ag Arrangement for taking up liquid analytes
GB2439050A (en) * 2006-06-13 2007-12-19 Zhanren Zhang Disposable chromatography device
US7482169B2 (en) 2002-07-15 2009-01-27 Phynexus, Inc. Low dead volume extraction column device
US7488603B2 (en) 2003-07-14 2009-02-10 Phynexus, Inc. Method and device for extracting an analyte
EP2024725A1 (en) * 2007-05-08 2009-02-18 Varian, Inc. Sample preparation device and method utilizing polymide tube
US7722820B2 (en) 2004-11-19 2010-05-25 Phynexus, Inc. Method and device for sample preparation
WO2010093998A2 (en) 2009-02-14 2010-08-19 Diffinity Genomics, Inc. System and methods for purifying biological materials
US8413489B2 (en) 2007-06-19 2013-04-09 Universal Bio Research Co., Ltd. Column tip processing device and column tip processing method
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US9114383B2 (en) 2003-07-14 2015-08-25 Phynexus, Inc. Method and device for extracting an analyte
EP2274099A4 (en) * 2008-03-28 2016-05-11 Biotix Inc Sample preparation devices and methods for processing analytes
US20170292123A1 (en) * 2014-08-13 2017-10-12 Axagarius Gmbh & Co. Kg Device for purifying nucleic acids

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437979A (en) * 1989-07-24 1995-08-01 Beckman Instruments, Inc. Solid phase system for sequential reactions
US5395521A (en) * 1991-05-31 1995-03-07 Board Of Regents, The University Of Texas System Automated column equilibration, column loading, column washing and column elution
DE4139664A1 (en) 1991-12-02 1993-06-03 Diagen Inst Molekularbio DEVICE AND METHOD FOR ISOLATING AND CLEANING NUCLEIC ACIDS
US5438128A (en) * 1992-02-07 1995-08-01 Millipore Corporation Method for rapid purifiction of nucleic acids using layered ion-exchange membranes
DE4321904B4 (en) * 1993-07-01 2013-05-16 Qiagen Gmbh Method for chromatographic purification and separation of nucleic acid mixtures
AU1315699A (en) * 1997-11-12 1999-05-31 Life Technologies, Inc. Device and methods for purifying biological molecules using low volumes of chromatographic and adsorptive media
CZ9900769A3 (en) * 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Use of tip with filter for making sorbent column of defined volume within the space underneath the filter
CZ9900770A3 (en) * 1999-03-04 2000-10-11 Petr Ing. Drsc. Hušek Process for preparing samples for analysis of amino acids and kit for this preparation
AT414209B (en) * 2000-03-17 2006-10-15 Greiner Bio One Gmbh COLLECTION TANK FOR LIQUIDS
JP2001281117A (en) * 2000-03-24 2001-10-10 Millipore Corp Sample adjusting device and sample adjusting device forming method
US7374724B2 (en) 2001-05-29 2008-05-20 Tecan Trading Ag Device for processing samples, use of the device, and method for producing the device
DE602005022196D1 (en) 2004-07-23 2010-08-19 Biosystem Dev Llc DEVICE FOR AN IMMUNOASSAY AND METHOD FOR THEIR USE
DE102005005437A1 (en) * 2005-02-05 2006-08-10 Eppendorf Ag Filter pipette tip
US8012349B2 (en) 2006-11-20 2011-09-06 Orbital Biosciences, Llc Small volume unitary molded filters and supports for adsorbent beds
US10851368B2 (en) 2015-04-23 2020-12-01 Aj Innuscreen Gmbh Device and process for automated extraction of nucleic acids
DE102015211393A1 (en) 2015-06-19 2016-12-22 Aj Innuscreen Gmbh Device and method for the automated extraction of nucleic acids
DE102015211394B4 (en) 2015-06-19 2022-07-28 Ist Innuscreen Gmbh Device and method for extracting nucleic acids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2452274A1 (en) * 1974-11-04 1976-05-06 Wuest Heinz Dr Med Appts for sepn of substances from solns - by extraction, adsorption, ion-exchange etc., esp. in medical tests
US3985032A (en) * 1975-11-13 1976-10-12 Centaur Chemical Co. Micropipette filter tips
FR2498331A1 (en) * 1981-01-20 1982-07-23 Kadouche Jean Container for immunological tests e.g. antigen identification - having reagent molecules, e.g. antibodies, fixed to inner face of pipette cone point
EP0198413A2 (en) * 1985-04-12 1986-10-22 E.I. Du Pont De Nemours And Company Rapid assay processor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3211309A1 (en) * 1982-03-26 1983-09-29 Metin Dipl.-Ing. 6100 Darmstadt Colpan CHROMATOGRAPHIC METHOD FOR INSULATING MACROMOLECULES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2452274A1 (en) * 1974-11-04 1976-05-06 Wuest Heinz Dr Med Appts for sepn of substances from solns - by extraction, adsorption, ion-exchange etc., esp. in medical tests
US3985032A (en) * 1975-11-13 1976-10-12 Centaur Chemical Co. Micropipette filter tips
FR2498331A1 (en) * 1981-01-20 1982-07-23 Kadouche Jean Container for immunological tests e.g. antigen identification - having reagent molecules, e.g. antibodies, fixed to inner face of pipette cone point
EP0198413A2 (en) * 1985-04-12 1986-10-22 E.I. Du Pont De Nemours And Company Rapid assay processor

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0691148A2 (en) * 1991-04-03 1996-01-10 The Perkin-Elmer Corporation A method for separating double stranded DNA from single stranded DNA or RNA
EP0691148A3 (en) * 1991-04-03 1996-01-24 Perkin Elmer Corp
WO1993003374A3 (en) * 1991-07-26 1993-05-27 Univ Schiller Jena Method and apparatus for the analysis of agglutination reactions
WO1993003374A2 (en) * 1991-07-26 1993-02-18 Friedrich-Schiller-Universität Jena Method and apparatus for the analysis of agglutination reactions
WO1993019368A1 (en) * 1992-03-18 1993-09-30 Abion Ohg Dr. Erhardt U. Maier One-way reaction vessel for the solid-phase immunological analysis of, and a method of measuring constituents which can be determined via immune reactions
US5556598A (en) * 1992-09-18 1996-09-17 Amersham International Plc. Device and method for affinity separation
EP0587951A1 (en) * 1992-09-18 1994-03-23 AMERSHAM INTERNATIONAL plc Cell nuclei capture method and device used therefor
US5447864A (en) * 1992-09-18 1995-09-05 Amersham International Limited Capture method for cell nucei using a DNA mesh
US5833927A (en) * 1992-09-18 1998-11-10 Amersham International Plc Device and method for affinity separation
EP0688426A1 (en) * 1993-03-08 1995-12-27 WAINWRIGHT, Norman Aligned fiber diagnostic chromatography
EP0688426A4 (en) * 1993-03-08 1996-01-31
US5876918A (en) * 1993-03-08 1999-03-02 Hydros, Inc. Aligned fiber diagnostic chromatography with positive and negative controls
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US6998047B1 (en) 1997-02-26 2006-02-14 Millipore Corporation Cast membrane structures for sample preparation
EP1015098A1 (en) * 1997-02-26 2000-07-05 Millipore Corporation Cast membrane structures for sample preparation
EP1015098A4 (en) * 1997-02-26 2000-08-09 Millipore Corp Cast membrane structures for sample preparation
US6200474B1 (en) 1997-02-26 2001-03-13 Millipore Corporation Cast membrane structures for sample prepartion
US6635201B1 (en) 1997-02-26 2003-10-21 Millipore Corporation Cast membrane structures for sample preparation
US6875354B1 (en) 1997-02-26 2005-04-05 Millipore Corporation Cast membrane structures for sample preparation
US6830717B2 (en) 1997-02-26 2004-12-14 Millipore Corporation Cast membrane structures for sample preparation
DE19806780C1 (en) * 1998-02-18 1999-07-01 November Ag Molekulare Medizin Apparatus to isolate and purify nucleic acids
US7163660B2 (en) 2000-05-31 2007-01-16 Infineon Technologies Ag Arrangement for taking up liquid analytes
EP1362126A2 (en) * 2001-01-17 2003-11-19 Kemmons A. Tubbs An integrated high throughput system for the analysis of biomolecules
EP1362126A4 (en) * 2001-01-18 2004-07-21 Kemmons A Tubbs An integrated high throughput system for the analysis of biomolecules
EP1485179A1 (en) * 2002-03-19 2004-12-15 Waters Investments Limited Device for solid phase extraction and method for purifying samples prior to analysis
EP1485179A4 (en) * 2002-03-19 2007-08-08 Waters Investments Ltd Device for solid phase extraction and method for purifying samples prior to analysis
JP2005521041A (en) * 2002-03-19 2005-07-14 ウオーターズ・インベストメンツ・リミテツド Solid phase extraction apparatus and method for purifying a sample before analysis
US7482169B2 (en) 2002-07-15 2009-01-27 Phynexus, Inc. Low dead volume extraction column device
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
US7488603B2 (en) 2003-07-14 2009-02-10 Phynexus, Inc. Method and device for extracting an analyte
US9114383B2 (en) 2003-07-14 2015-08-25 Phynexus, Inc. Method and device for extracting an analyte
US7837871B2 (en) 2003-07-14 2010-11-23 Phynexus, Inc. Method and device for extracting an analyte
US7722820B2 (en) 2004-11-19 2010-05-25 Phynexus, Inc. Method and device for sample preparation
GB2439050A (en) * 2006-06-13 2007-12-19 Zhanren Zhang Disposable chromatography device
EP2024725A1 (en) * 2007-05-08 2009-02-18 Varian, Inc. Sample preparation device and method utilizing polymide tube
US8883089B2 (en) 2007-05-08 2014-11-11 Agilent Technologies, Inc. Sample preparation device and method utilizing polyamide tube
EP2024725A4 (en) * 2007-05-08 2009-06-17 Varian Inc Sample preparation device and method utilizing polymide tube
US8413489B2 (en) 2007-06-19 2013-04-09 Universal Bio Research Co., Ltd. Column tip processing device and column tip processing method
EP2274099A4 (en) * 2008-03-28 2016-05-11 Biotix Inc Sample preparation devices and methods for processing analytes
WO2010093998A2 (en) 2009-02-14 2010-08-19 Diffinity Genomics, Inc. System and methods for purifying biological materials
US20170292123A1 (en) * 2014-08-13 2017-10-12 Axagarius Gmbh & Co. Kg Device for purifying nucleic acids

Also Published As

Publication number Publication date
DE3717211A1 (en) 1988-12-01
DE3717211C2 (en) 1991-02-28

Similar Documents

Publication Publication Date Title
WO1988009201A1 (en) Process and device for separating and cleaning molecules
EP0616639B1 (en) Device and process for isolating and purifying nucleic acids
EP1121460B1 (en) Methods and means for isolating and purifying nucleic acids on surfaces
DE4321904B4 (en) Method for chromatographic purification and separation of nucleic acid mixtures
EP3286312B1 (en) Device and method for extracting nucleic acids
EP0555270A1 (en) Process for insulating nucleic acids from cell suspensions.
EP0738733A2 (en) Method for isolating nucleic acids
EP1075546A1 (en) Method and device for isolating nucleic acids
EP1771242B1 (en) Method for efficient isolation of nucleic acids
EP1123980B1 (en) System for simple nucleic acid analysis
DE69817818T2 (en) UNIFORM DEVICE AND METHOD FOR CONCENTRATING AND CLEANING BIOLOGICAL MOLECULES
DE202015104264U1 (en) Device for the purification of nucleic acids
EP1242816B1 (en) Chromatography material and a method using same
DE10018788B4 (en) Processing proteins from gels for mass spectrometric analysis
EP2129464A1 (en) Device for receiving, treating, and storing small volume samples
DE102007005655A1 (en) Device and method for the purification of nucleic acids
DE10238630A1 (en) Process for isolating biological macromolecules and device for carrying out this process

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE